Skip to main content
. 2015 May 8;29(6):732–741. doi: 10.1038/eye.2015.58

Figure 3.

Figure 3

A 30-year-old man with CSC demonstrating poor response after single intravitreal bevacizumab treatment. Fluorescein angiography (a), indocyanine green angiography (b), SD-OCT at baseline with relatively thin choroid (289 μm, white arrow) (c). Slightly decreased, but remaining SRF was noted at 1 month after intravitreal bevacizumab (d).